Market revenue in 2023 | USD 29.3 million |
Market revenue in 2030 | USD 150.0 million |
Growth rate | 26.3% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.57% in 2023. Horizon Databook has segmented the France peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
France is expected to witness significant growth over the forecast period owing to various initiatives undertaken by public & private organizations focusing on the development and commercialization of novel therapeutics products.
Moreover, increasing investments in developing novel advanced therapy products in the country are anticipated to support market growth over the forecast period. Such proactive government initiatives increase accessibility to treatment options, such as peptide-based drugs, thereby playing a key role in reducing the national disease burden.
The rising prevalence of target diseases is further propelling the need for effective therapeutics in the market. Moreover, cardiovascular diseases are the second leading cause of death in France, affecting someone in France every 4 minutes.
Horizon Databook provides a detailed overview of country-level data and insights on the France peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into France peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account